Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Coya Therapeutics (COYA) FCF Margin (2023 - 2025)

Coya Therapeutics' FCF Margin history spans 3 years, with the latest figure at 31.72% for Q3 2025.

  • For Q3 2025, FCF Margin changed N/A year-over-year to 31.72%; the TTM value through Sep 2025 reached 304.48%, down 19856.0%, while the annual FY2024 figure was 289.49%, 10308.0% down from the prior year.
  • FCF Margin for Q3 2025 was 31.72% at Coya Therapeutics, up from 3528.56% in the prior quarter.
  • Across five years, FCF Margin topped out at 1691.82% in Q1 2024 and bottomed at 123451.18% in Q4 2024.
  • The 3-year median for FCF Margin is 133.23% (2024), against an average of 18083.85%.
  • The largest annual shift saw FCF Margin tumbled -12341384bps in 2024 before it crashed -278855bps in 2025.
  • A 3-year view of FCF Margin shows it stood at 37.34% in 2023, then tumbled by -330535bps to 123451.18% in 2024, then surged by 100bps to 31.72% in 2025.
  • Per Business Quant, the three most recent readings for COYA's FCF Margin are 31.72% (Q3 2025), 3528.56% (Q2 2025), and 1096.72% (Q1 2025).